Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
World game at war: why some European nations have threatened a World Cup boycott 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
MENLO PARK, Calif., May 01, 2018 -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report first quarter financial results and provide a corporate update on May 8, 2018. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Conference Call Information
To participate, dial 1-800-239-9838 from the United States or 1-323-794-2551 internationally approximately 10 minutes before the start of the call. The passcode is 3450659.
A replay will be available through May 22, 2018 at 1-888-203-1112 from the United States and 1-719-457-0820 internationally. The passcode will be 3450659.
About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym® is the company’s first FDA-approved medication. Corcept has a large portfolio of proprietary compounds that modulate the effects of cortisol but not progesterone. Corcept owns extensive United States and foreign intellectual property covering the use of cortisol modulators in the treatment of a wide variety of serious disorders, including Cushing’s syndrome. It also holds composition of matter patents covering its selective cortisol modulators.
CONTACT:
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783
[email protected]
www.corcept.com
